HEALTH TECHNOLOGY

Viemed Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc. | July 06, 2022 | Read time : 1 min

Viemed Announces

Viemed Healthcare, Inc. a national leader in respiratory care and technology-enabled home medical equipment services, announced a third peer-reviewed and published study demonstrating the benefits of non-invasive ventilation at home The study, titled “Early Initiation of Non-Invasive Ventilation at Home Improves Survival and Reduces Healthcare Costs in COPD Patients with Chronic Hypercapnic Respiratory Failure: A Retrospective Cohort Study” was published in Respiratory Medicine, an internationally renowned scientific journal devoted to respiratory medical research.

In addition to the significant clinical benefits demonstrated in previously published papers, this study demonstrates that NIVH improves health outcomes while simultaneously driving down overall healthcare costs. The study was also designed to investigate how the timing of NIVH initiation affected the outcomes. The results showed that the clinical and financial benefits of NIVH are greatest when therapy begins immediately following the diagnosis.”

Dr. William Frazier, Viemed’s Chief Medical Officer and co-author of the study

Using the 100% research identifiable fee-for-service Medicare claims from 2016 through 2020, the researchers found that using NIVH to treat chronic obstructive pulmonary disease with chronic hypercapnic respiratory failure is associated with significant reductions in mortality, hospitalizations, and total Medicare costs. In terms of cost-savings, Medicare expenditures for the year following NIVH initiation decreased by $5,484 compared to controls if treatment was begun within seven days of diagnosis. The cost reduction was $3,412 if NIVH was begun within 15 days of diagnosis. For patients whose therapy began more than 15 days after diagnosis, NIVH use was cost neutral and not associated with an increase in Medicare expenditures.

The primary clinical benefit was a reduced mortality in patients treated with NIVH. When a patient began therapy within seven days of diagnosis, the risk of death was reduced by 43%. Those patients who began therapy between eight and 15 days following diagnosis showed a mortality reduction of 31%, and patients who began therapy between 16 and 30 days following diagnosis showed a mortality reduction of 16%.

“NIVH is becoming widely accepted by clinicians as the standard of care for hypercapnic COPD-CRF treatment and this evidence supporting early initiation will help us to communicate the clinical and economic benefits to payors and partners,” said Casey Hoyt, Viemed’s CEO. “By accessing and treating more patients sooner, we can save lives, reduce hospital readmissions, and save money at the same time.”

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. 

Spotlight

Alliance Healthcare is a leading international provider of pharmaceutical wholesaling, logistics, support with clinical trials and other innovative healthcare services and solutions to independent pharmacists and pharmaceutical manufacturers across Europe and beyond.

Spotlight

Alliance Healthcare is a leading international provider of pharmaceutical wholesaling, logistics, support with clinical trials and other innovative healthcare services and solutions to independent pharmacists and pharmaceutical manufacturers across Europe and beyond.

Related News

HEALTHTECH SECURITY,FUTURE OF HEALTHCARE

Sightpath Medical Acquires Accusite Surgical

Sightpath Medical | November 22, 2022

Sightpath Medical, the leading provider of mobile ophthalmic services for cataract and refractive surgery, announced that it has acquired Accusite Surgical, a cataract surgery equipment outsourcing company. Founded in 1991, Sightpath Medical delivers custom access to advanced ophthalmic equipment, instruments, and services to facilities and surgeons across the United States. Through its patented technology, the company was the first to mobilize phacoemulsification machines, excimer lasers, the IntraLase Femtosecond Laser, and the LenSx Femtosecond Laser. Sightpath Medical has earned the trust of medical professionals and patients nationwide through the quality of its equipment, the skill of its employees, and the dedication and responsiveness of its staff. Accusite Surgical is a mobile cataract surgical company that outsources state-of-the-art equipment, technology, and certified staff to surgeons, ambulatory surgical centers, and hospitals. For over 28 years, the company has assisted in more than 200,000 procedures throughout the Southeastern U.S. In connection with the transaction, D. Lynn Godfrey, Founder and Chief Executive Officer of Accusite Surgical, will join Sightpath Medical as Chief Strategy Officer. “This strategic combination bolsters Sightpath Medical’s market-leading position and enhances our ability to deliver variable, tailored access to the expert personnel, equipment, and supplies surgeons need to provide critical eye care. We are delighted to begin integrating the Accusite Surgical business into ours and are equally excited to welcome Lynn Godfrey, who is an experienced and creative executive, to our management team. We look forward to growing Sightpath Medical together.” Joel Gaslin, President and CEO of Sightpath Medical Mr. Godfrey added, “After 28 years, I began exploring the long-term options for my business and quickly determined that the Sightpath Medical executive team and its financial partner, MGG Investment Group, were the right partners for Accusite Surgical. We are closely aligned on our core mission of helping surgeons and their referring Optometrists provide patients with excellent eye care and, ultimately, better vision. I am thrilled to commence Accusite Surgical’s next chapter as part of Sightpath Medical.” About Sightpath Medical Sightpath Medical is the leading U.S. provider of mobile ophthalmic services for cataract, refractive and laser-assisted surgery. Working alongside more than 1,200 surgeons and the staffs of their surgical facilities for more than 30 years, Sightpath Medical is the market-leading choice for surgeons, ASCs, and hospitals due to our proven ability to deliver the staff, equipment, and supplies wherever and whenever they are needed – regardless of geography. About Accusite Surgical For nearly three decades, Accusite Surgical has been a leading provider of state-of-the-art equipment, supplies, and support for cataract surgery in the Southeastern United States. Accusite Surgical is a trusted partner to ASCs and hospitals and ophthalmologists for cataract surgery services and is committed to helping surgeons grow their practices while delivering superior outcomes for patients.

Read More

DIGITAL HEALTHCARE

CipherHealth and SADA Collaborate to Improve Patient Care Via Looker

CipherHealth | January 06, 2023

CipherHealth, a leader in patient engagement technology and communication solutions, recently teamed up with SADA, an award-winning Google Cloud Partner, to use Google Cloud's Looker to collect socioeconomic data to improve patient care. With this new feature, CipherHealth aims to empower healthcare leaders by enabling them to collect large volumes of data and assist patients and medical professionals at each point of the care journey. Earlier, CipherHealth's platform gave doctors and nurses complete conversational and clinical information about each patient. It worked with SADA, a company that knows how to set up and run Google Cloud's analytics platform Looker, to add self-service analytics to the platform and make it more useful. With the help of Looker Embedded Analytics, CipherHealth has made it easier for its clients to access this data for analysis and visualization at any time during the patient's life. As a result of the partnership, CipherHealth's clients, which include 500 hospitals across the country, will now have access to patient data about social determinants of health (SDOH). Also, they can use in-built analytics to divide patient groups and send personalized messages to each of them separately. With this information, CipherHealth's clients can zero in on a specific patient and find out what kind of treatment they need, along with any special accommodations (like if they have trouble making appointments). CipherHealth is HIPAA-compliant, meaning it may safely analyze and transfer clients' protected health information (PHI) over the internet. The company believes combining SADA with Google Cloud can give its clients a new view of their patient populations. It will also allow the company to make changes to its care delivery that are good for patients. In line with this, SADA said that the integration of Looker from Google Cloud improves the patient experience for CipherHealth and its clients. About CipherHealth CipherHealth is a proven technology solutions partner dedicated to improving patient communication and care. Since 2009, the company has helped build the market for patient engagement by making innovative tools that help providers give excellent care. The range of patient engagement programs from CipherHealth sets new standards for care and provides healthcare businesses with the tools they need to have meaningful conversations with their patients.

Read More

HEALTHTECH SECURITY, FUTURE OF HEALTHCARE

Magellan Healthcare Teams with Kyo to Improve Autism Outcomes

Magellan Health | December 07, 2022

Magellan Healthcare, Inc., the behavioral health division of Magellan Health, Inc., announced the launch of a first-to-market, value-based collaboration with Kyo Autism Therapy, LLC, a California-based Applied Behavior Analysis provider, to drive meaningful and objectively measurable outcomes for children with autism spectrum disorder. Magellan and Kyo will develop, build and test a value-based model for treatment planning and delivery to continuously improve care for children with ASD and help the families who care for them. Findings will be used to establish evidence-based practices and drive outcomes-based programs across the ABA industry. Magellan manages ABA services through Magellan Autism Connections®, a first-to-market and one-of-a-kind solution that offers individualized care planning to optimize treatment and services. Enhanced care coordination ensures goals are met, with services that include intensive support to caregivers. Magellan Autism Connections® includes a fully vetted and credentialed provider network, of which Kyo is a member, the members of which share the company’s mission to deliver evidence-based ASD treatment that drives positive outcomes. When surveyed, 93% of Magellan Autism Connections® members’ caregivers say service providers work well with them and their child and caregivers have learned how to use ABA techniques to help their child. In addition, 80% of commercial Magellan Autism Connections® members make excellent progress at a cost 40% below the national average, and 75% of Medicaid members make excellent progress at a cost 62% below the national average. “At Magellan, we have deep clinical expertise in ABA that includes strong collaborations with well-respected providers such as Kyo. Together with Kyo’s individualized and customized approach to ABA therapy, we can jointly improve the quality of life for children with autism and their families.” Yagnesh Vadgama, BCBA, vice president, clinical care services for autism, Magellan Healthcare "ABA services have struggled to transition from a fee-for-service to a value-based model," said Colin Davitian, CEO of Kyo. "Our collaboration with Magellan will help change the paradigm and make ABA treatment more individualized and outcomes-driven.” About Magellan Health Magellan Health, Inc. a is a leader in managing the fastest growing, most complex areas of health, including special populations, and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. About Magellan Healthcare Magellan Healthcare, Inc., the healthcare business unit of Magellan Health, Inc., offers solutions for complex conditions in the areas of behavioral health and medical specialty treatment. Magellan Healthcare and its subsidiaries serve commercial health plans, employers, state and local governments, and the Federal government, including the Department of Defense. About Kyo Kyo Autism Therapy, LLC is a leader in behavior therapy for individuals with autism. With its staff of highly-educated, expertly trained professionals, Kyo works to advance the lives of individuals and families with autism and other special needs through compassionate, evidence-based treatment. Since being founded in 2005, Kyo has expanded from its San Francisco base to serve families across California and the U.S.

Read More